共 27 条
- [21] Tumor-derived extracellular vesicles inhibit HGF/c-Met and EGF/EGFR pathways to accelerate the radiosensitivity of nasopharyngeal carcinoma cells via microRNA-142-5p deliveryCell Death Discovery, 8Changyu ZhuXiaolei JiangHua XiaoJianmei Guan
- [22] Anti-tumor Activity of Bufalin by Inhibiting c-MET Mediated MEK/ERK and PI3K/AKT Signaling Pathways in Gallbladder CancerJOURNAL OF CANCER, 2020, 11 (11): : 3114 - 3123Qian, LiqiangSu, HaoyuanWang, GangLi, BinShen, GenhaiGao, Quangen
- [23] Silybum marianum total extract, silymarin and silibinin abate hepatocarcinogenesis and hepatocellular carcinoma growth via modulation of the HGF/c-Met, Wnt/β-catenin, and PI3K/Akt/mTOR signaling pathwaysBIOMEDICINE & PHARMACOTHERAPY, 2022, 145Yassin, Nour Y. S.AbouZid, Sameh F.El-Kalaawy, Asmaa M.Ali, Tarek M.Almehmadi, Mazen M.Ahmed, Osama M.
- [24] Interim results from a first-in-human study with AMG102, a fully human monoclonal antibody that neutralizes hepatocyte growth factor (HGF), the ligand to c-Met receptor, in patients (pts) with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)Gordon, M. S.Mendelson, D. S.Sweeney, C.Erbeck, N.Patel, R.Kakkar, T.Yan, L.Eckhardt, S. G.Gore, L.
- [25] A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convectionenhanced delivery for adult patients with recurrent malignant glioma (MG).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Desjardins, AnnickChandramohan, VidyalakshmiLandi, Daniel B.Johnson, Margaret O.Khasraw, MustafaPeters, Katherine B.Low, JustinHerndon, James EmmettThreatt, StevieBullock, Chevelle A.Lipp, Eric S.Sampson, John H.Friedman, Allan H.Friedman, Henry S.Ashley, David M.Knorr, DavidBigner, Darell D.
- [26] Anti-Cytokeratin CAM5.2 (BD) does not act as a substitute of the CK8/18 monoclonal antibody. Comment on: 'Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and-2 in spinal chordoma'. Histopathology 2009; 54; 607-613HISTOPATHOLOGY, 2010, 56 (06) : 810 - 811Naka, Takahiko
- [27] PHASE 1/1B TRIAL OF FC-ENGINEERED ANTI-CD40 AGONIST MONOCLONAL ANTIBODY (2141-V11) INFUSED WITH D2C7-IT IN ENHANCING DISEASE BY CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (RMG)NEURO-ONCOLOGY, 2023, 25Desjardins, AnnickChandramohan, VidyaLandi, DanielPeters, KatherineJohnson, Margaret O.Low, JustinKhasraw, MustafaThreatt, StevieBullock, ChevelleHerndon, JamesLipp, EricFriedman, AllanFriedman, HenryAshley, DavidOsorio, JuanRavetch, JeffreyBigner, Darell